Investor Update
Basel, 25 August 2011
Roche Investor Science Call from ESC 2011:
Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE
Monday, 29 August 2011, Paris, France
We kindly invite investors and analysts to participate in a conference call that will be held during the European Society of Cardiology Congress taking place from 27-31 August 2011 in Paris.
On the call, Roche will discuss new data from two phase IIb studies with the CETP modulator dalcetrapib. The studies investigated dalcetrapib’s effects on vascular function (dal-VESSEL) and on atherosclerotic disease progression (dal-PLAQUE). Further, Roche will provide an overall update on the CardioMetabolism franchise. The presentation will be followed by a Q&A session.
The conference call will take place on:
Monday, 29 August 2011 3:00pm to 4:00pm CEST (European time) 9:00am to 10:00am EDT (Eastern time) 2:00pm to 3:00pm BST (London time)
Program:
Introduction
Karl Mahler, Head of Investor Relations
CETP modulation: A new frontier in addressing cardiovascular risk
Dr. David Kallend, Global Clinical Science Leader for dalcetrapib, Roche
Dalcetrapib phase IIb endothelial function study: dal-VESSEL
Dr. David Kallend, Global Clinical Science Leader for dalcetrapib, Roche
Dalcetrapib phase IIb imaging study: dal-PLAQUE
Ahmed A. Tawakol MD, Massachusetts General Hospital Boston, MA
Cardiometabolism franchise: overview and update on phase III programs
Dr. Fouzia Laghrissi Thode, Global Product Strategy Head for Metabolism and Anemia, Roche
Questions & Answers
F. Hoffmann-La Roche Ltd CH-4070 Basel Investor Relations Tel. +41-(0)61-688 88 80 email: Fax +41-(0)61-691 00 14 investor.relations@roche.com http://ir.roche.com

Télécharger le communiqué
!:!iframe http://www.nextnews.fr/upload/fr/nextnews%5Froche%5Froche%5Finvestor%5Fscience%5Fcall%5Ffrom%5Fesc%5F2011%5F56448%2EPDF!:!

En partenariat avec NextNews